Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,620 matching trials from the live ClinicalTrials.gov search.
Conditions
Geographic Atrophy
Interventions
Sham, Lampalizumab
Other · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
60 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
36
States / cities
Mesa, Arizona • Tucson, Arizona • Springdale, Arkansas + 33 more
Conditions
Neovascularization, Choroidal, Macular Degeneration, Age-Related
Interventions
Faricimab, Ranibizumab, Sham Procedure
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 22 more
Conditions
Macular Edema, Uveitis
Interventions
triamcinolone, ranibizumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Macular Edema, Diabetes Mellitus
Interventions
Dexamethasone intravitreal implant, Steroid plus NSAID eye drop combination therapy
Drug
Lead sponsor
Retinal Consultants of Arizona
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham control of BI 764524
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Dothan, Alabama • Beverly Hills, California • Palo Alto, California + 10 more
Conditions
Central Serous Chorioretinopathy
Interventions
Intravitreal Aflibercept Injection
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Huntingdon Valley, Pennsylvania • Philadelphia, Pennsylvania
Conditions
Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
Interventions
Remigromig, Aflibercept 2.0 mg
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
55
States / cities
Scottsdale, Arizona • Glendale, California • Modesto, California + 34 more
Conditions
Neovascular Age Related Macular Degeneration
Interventions
Squalamine lactate, Vehicle control
Drug
Lead sponsor
Ohr Pharmaceutical Inc.
Industry
Eligibility
50 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
20
States / cities
Tucson, Arizona • Bakersfield, California • Beverly Hilss, California + 17 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Ocular Blood Flow Imaging for Glaucoma Assessment

NCT05726058
Conditions
Glaucoma
Interventions
XyCAM with oxygen
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Macular Degeneration
Interventions
Rheopheresis blood filtration
Device
Lead sponsor
OccuLogix
Industry
Eligibility
0 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
8
States / cities
Beverly Hills, California • Coral Gables, Florida • Fort Myers, Florida + 5 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Study of the Optic Disc Parameters

NCT02277119
Conditions
Normal Healthy Subjects With No Known Ocular Diseases, Glaucomatous Eyes, Eyes With Retinal Diseases
Interventions
Maestro, iVue
Device
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Pomona, California • New York, New York
Conditions
Age-Related Macular Degeneration
Interventions
E10030, ranibizumab, E10030 sham intravitreal injection
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
50
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 44 more
Conditions
Epiretinal Membrane, Dry Age Related Macular Degeneration, Macular Abnormalities, Retina Disease, Vitreoretinal Abnormality, Intraretinal Hyporeflective Space, Subretinal Hyporeflective Space, IS/OS (Ellipsoid Zone) Disruption, Retinal Pigment Epithelium (RPE) Elevation, Retinal Pigment Epithelium (RPE) Atrophy
Interventions
PathFinder 1.0 on CIRRUS HD-OCT
Device
Lead sponsor
Carl Zeiss Meditec-Dublin CoCe
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
6
States / cities
Tucson, Arizona • Mountain View, California • San Francisco, California + 3 more
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Conditions
Age-Related Macular Degeneration
Interventions
Fovista®, bevacizumab, ranibizumab, aflibercept
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 21 more
Conditions
Nonproliferative Diabetic Retinopathy
Interventions
AKB-9778, Placebo
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
53
States / cities
Phoenix, Arizona • Arcadia, California • Bakersfield, California + 47 more
Conditions
Geographic Atrophy
Interventions
STL303, Placebo
Drug
Lead sponsor
Sitala Bio LTD
Industry
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
16
States / cities
Bakersfield, California • Beverly Hills, California • Aurora, Colorado + 12 more
Terminated No phase listed Observational

Ocular Imaging Study Using Advanced OCT

NCT02827071
Conditions
Retinal Vascular Disorder, Macular Degeneration
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 115 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Age-Related Macular Degeneration
Interventions
AG-013,958
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
30
States / cities
Mesa, Arizona • Oro Valley, Arizona • Phoenix, Arizona + 27 more
Conditions
Retinoschisis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
9 Months to 100 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Bethesda, Maryland • Rochester, Michigan
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
81
States / cities
Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more
Conditions
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3, THR-149 0.13mg, THR-149 0.13mg + aflibercept 2mg, aflibercept 2mg + THR-149 0.13mg, Aflibercept 2mg
Drug
Lead sponsor
Oxurion
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 32 more
Conditions
Chronic Low-back Pain, Chronic Pain, Fibromyalgia
Interventions
Green Light stimulation, Equal Energy White stimulation, S-cone modulating white light
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed Not applicable Interventional Results available

Low Cost OCT for Point of Care

NCT03323307
Conditions
Optical Coherence Tomography (OCT) of the Retina
Interventions
OCT imaging
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina